Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma

CompletedOBSERVATIONAL

Enrollment

2,000

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions

NSCLC

Interventions

OTHER

Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome

Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.

All Listed Sponsors

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Sana Klinikum Hof

UNKNOWN

lead

Klinikum Bayreuth GmbH

INDUSTRY

NCT04276025 - Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma | Biotech Hunter | Biotech Hunter